Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and Chief Executive Officer, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT. Seres will highlight its plans to advance its biotherapeutics pipeline, focusing on SER-155, the Company’s lead program. The Company recently announced that SER-155 received Breakthrough Therapy designation for the reduction of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant, to treat hematological malignancies, from the US Food and Drug Administration (FDA). This designation was supported by Phase 1b placebo-controlled study results in patients undergoing allo-HSCT demonstrating that SER-155 was associated with a significant reduction in BSIs (77% relative risk reduction), a signif
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) [Yahoo! Finance]Yahoo! Finance
- FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)GlobeNewswire
- Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Seres Therapeutics to Participate in Piper Sandler Healthcare ConferenceGlobeNewswire
MCRB
Earnings
- 11/13/24 - Beat
MCRB
Sec Filings
- 11/19/24 - Form 4
- 11/19/24 - Form 4
- 11/19/24 - Form 4
- MCRB's page on the SEC website